Emerging therapies for refractory angina.

Daniel Satran, Jay H. Traverse, Gregory W. Barsness, Amir Lerman, Robert D. Simari, Anil K. Poulose, Randall K. Johnson, Timothy D. Henry

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In recent years, improvements in both pharmacologic and revascularization therapies have greatly increased life expectancy for patients with coronary artery disease (CAD). As patients with more extensive CAD live longer, many develop myocardial ischemia and clinical angina that is not amenable to traditional revascularization therapy. Patients with severe, symptomatic, chronic CAD have been described as having refractory angina; they have also been termed "no-option" patients. This article discusses clinical management of this unique and growing group of patients and emerging therapeutic options including pharmacologic agents, enhanced external counterpulsation therapy, therapeutic angiogenesis, neurostimulation, and transmyocardial revascularization.

Original languageEnglish (US)
Pages (from-to)36-39
Number of pages4
JournalMinnesota Medicine
Volume91
Issue number1
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

Coronary Artery Disease
Counterpulsation
Therapeutics
Life Expectancy
Myocardial Ischemia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Satran, D., Traverse, J. H., Barsness, G. W., Lerman, A., Simari, R. D., Poulose, A. K., ... Henry, T. D. (2008). Emerging therapies for refractory angina. Minnesota Medicine, 91(1), 36-39.

Emerging therapies for refractory angina. / Satran, Daniel; Traverse, Jay H.; Barsness, Gregory W.; Lerman, Amir; Simari, Robert D.; Poulose, Anil K.; Johnson, Randall K.; Henry, Timothy D.

In: Minnesota Medicine, Vol. 91, No. 1, 01.2008, p. 36-39.

Research output: Contribution to journalArticle

Satran, D, Traverse, JH, Barsness, GW, Lerman, A, Simari, RD, Poulose, AK, Johnson, RK & Henry, TD 2008, 'Emerging therapies for refractory angina.', Minnesota Medicine, vol. 91, no. 1, pp. 36-39.
Satran D, Traverse JH, Barsness GW, Lerman A, Simari RD, Poulose AK et al. Emerging therapies for refractory angina. Minnesota Medicine. 2008 Jan;91(1):36-39.
Satran, Daniel ; Traverse, Jay H. ; Barsness, Gregory W. ; Lerman, Amir ; Simari, Robert D. ; Poulose, Anil K. ; Johnson, Randall K. ; Henry, Timothy D. / Emerging therapies for refractory angina. In: Minnesota Medicine. 2008 ; Vol. 91, No. 1. pp. 36-39.
@article{570d0312fc6341a1adc6405597a737fe,
title = "Emerging therapies for refractory angina.",
abstract = "In recent years, improvements in both pharmacologic and revascularization therapies have greatly increased life expectancy for patients with coronary artery disease (CAD). As patients with more extensive CAD live longer, many develop myocardial ischemia and clinical angina that is not amenable to traditional revascularization therapy. Patients with severe, symptomatic, chronic CAD have been described as having refractory angina; they have also been termed {"}no-option{"} patients. This article discusses clinical management of this unique and growing group of patients and emerging therapeutic options including pharmacologic agents, enhanced external counterpulsation therapy, therapeutic angiogenesis, neurostimulation, and transmyocardial revascularization.",
author = "Daniel Satran and Traverse, {Jay H.} and Barsness, {Gregory W.} and Amir Lerman and Simari, {Robert D.} and Poulose, {Anil K.} and Johnson, {Randall K.} and Henry, {Timothy D.}",
year = "2008",
month = "1",
language = "English (US)",
volume = "91",
pages = "36--39",
journal = "Minnesota medicine.",
issn = "0026-556X",
publisher = "Minnesota Medical Association",
number = "1",

}

TY - JOUR

T1 - Emerging therapies for refractory angina.

AU - Satran, Daniel

AU - Traverse, Jay H.

AU - Barsness, Gregory W.

AU - Lerman, Amir

AU - Simari, Robert D.

AU - Poulose, Anil K.

AU - Johnson, Randall K.

AU - Henry, Timothy D.

PY - 2008/1

Y1 - 2008/1

N2 - In recent years, improvements in both pharmacologic and revascularization therapies have greatly increased life expectancy for patients with coronary artery disease (CAD). As patients with more extensive CAD live longer, many develop myocardial ischemia and clinical angina that is not amenable to traditional revascularization therapy. Patients with severe, symptomatic, chronic CAD have been described as having refractory angina; they have also been termed "no-option" patients. This article discusses clinical management of this unique and growing group of patients and emerging therapeutic options including pharmacologic agents, enhanced external counterpulsation therapy, therapeutic angiogenesis, neurostimulation, and transmyocardial revascularization.

AB - In recent years, improvements in both pharmacologic and revascularization therapies have greatly increased life expectancy for patients with coronary artery disease (CAD). As patients with more extensive CAD live longer, many develop myocardial ischemia and clinical angina that is not amenable to traditional revascularization therapy. Patients with severe, symptomatic, chronic CAD have been described as having refractory angina; they have also been termed "no-option" patients. This article discusses clinical management of this unique and growing group of patients and emerging therapeutic options including pharmacologic agents, enhanced external counterpulsation therapy, therapeutic angiogenesis, neurostimulation, and transmyocardial revascularization.

UR - http://www.scopus.com/inward/record.url?scp=41949101508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949101508&partnerID=8YFLogxK

M3 - Article

VL - 91

SP - 36

EP - 39

JO - Minnesota medicine.

JF - Minnesota medicine.

SN - 0026-556X

IS - 1

ER -